• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Prostate-Specific Protein Can Be Used to Diagnose BPH in Middle-Aged Dogs

April 15, 2017
JoAnna Pendergrass, DVM

Measuring canine prostate-specific arginine esterase levels can be an alternative or complementary method to accurately diagnose benign prostatic hyperplasia in middle-aged dogs.

Measuring canine prostate-specific arginine esterase (CPSE) levels can be an alternative or complementary method to accurately diagnose benign prostatic hyperplasia (BPH) in middle-aged dogs, according to a study recently published in BMC Veterinary Research.

The authors wrote that systematic CPSE quantification “can increase the likelihood of early [diagnosis of BPH] in apparently healthy middle-aged dogs.”

Prostatic diseases frequently affect middle-aged and older intact dogs. BPH develops spontaneously, with its development primarily influenced by testosterone. Because BPH can negatively affect fertility, an early diagnosis is preferable. However, clinical signs of BPH can be transient, making an early diagnosis potentially challenging.

Ultrasound-confirmed prostatomegaly often provides a conclusive BPH diagnosis. However, BPH can resemble other prostatic diseases (e.g., squamous metaplasia, prostatitis) on ultrasound, highlighting the need for additional diagnostic tools, such as CPSE measurement, to accurately diagnose the disease.

CPSE is an androgen-dependent protein that is similar to the human prostate-specific antigen. A previous study reported higher serum CPSE levels in dogs with BPH than in normal dogs.

For the current study, the authors evaluated 60 intact adult male dogs, each of which underwent a comprehensive examination:

Advertisement
  • Physical and digital rectal exam
  • Cytologic evaluation
  • Serum CPSE measurement
  • Transabdominal ultrasound

Ultrasound findings were classified as suggestive of BPH, cystic prostatic hyperplasia, or prostatitis. Cytologic samples were classified as BPH, squamous metaplasia, or prostatitis. Dogs were grouped according to cytologic presence or absence of BPH:

  • Study group: n = 29, BPH positive
  • Control group: n = 31, BPH negative

ELISA was performed to measure serum CPSE levels, using the manufacturer-provided cut-off value of 61 ng/mL for BPH.

The authors calculated a correlation coefficient to determine how well CPSE results agreed with other diagnostic results regarding BPH positivity or negativity. Using cytology as the reference method, CPSE sensitivity and specificity were also calculated.

Clinical Examination, Ultrasound, and Cytologic Findings

Median weight was markedly higher in the study group (66 lb) than the control group (42 lb). In addition, study group dogs were older (median age, 9 years) than control group dogs (median age, 5 years). Notably, 7 of 29 study group dogs showed no clinical signs of BPH.

In the study group, 8 of 29 dogs had prostatitis; the authors noted that multiple diseases can concomitantly exist in the canine prostate. In the control group, prostatitis was present in 6 dogs and squamous metaplasia was present in 2 dogs.

CPSE Levels

Median CPSE levels were significantly higher in the study group (160.1 ng/mL) than in the control group (29.1 ng/mL). CPSE levels were significantly correlated with age and prostatic volume, but not weight. The nonsignificant correlation between CPSE and weight was notable, indicating that CPSE levels can be used to diagnose BPH in large breeds, or even in obese dogs for which digital rectal examination is not possible.

Testing Agreement

CPSE results showed high levels of agreement with the other diagnostic tests, with the highest level of agreement being with cytology.

In the study group, 1 of 29 dogs had a CPSE level below 61 ng/mL (false negative). In the control group, 3 of 31 dogs had a CPSE level markedly above 61 ng/mL (false positive); these 3 dogs had either prostatitis or squamous metaplasia. The authors determined a 97% sensitivity and 90% specificity for CPSE.

Conclusions

Taken together, these study results demonstrate the diagnostic accuracy of CPSE levels for detecting BPH in middle-aged dogs. In addition to diagnostic accuracy, the authors proposed using CPSE levels to assess success of BPH medical treatment.

Dr. JoAnna Pendergrass received her Doctor of Veterinary Medicine degree from the Virginia-Maryland College of Veterinary Medicine. Following veterinary school, she completed a postdoctoral fellowship at Emory University’s Yerkes National Primate Research Center. Dr. Pendergrass is the founder and owner of JPen Communications, a medical communications company.


Advertisement

Latest News

Free microchipping event to take place in Chicago

Zoo announces birth of critically endangered red wolf pups

Study reveals most pet parents wouldn't leave home to escape disaster if they couldn't bring pets

New ASAP Vet urgent care opens in Austin, Texas

View More Latest News
Advertisement